Full-Time

Sr IT Business Analysis Specialist

Tech Dev Biologics Clinical Manufacturing

Posted on 6/12/2026

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$126.8k - $164.1k/yr

+ Discretionary annual bonus + Discretionary stock-based long-term incentives

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

In Person

Category
IT & Security (1)
Required Skills
Python
R
Machine Learning
AWS
JIRA
Asana
Requirements
  • Bachelor's degree and 5+ years of relevant experience; OR Master's degree and 3+ years of relevant experience
  • Degree in computer science, information sciences or related field or equivalent experience
  • Strong communication, excellent research skills, and learning agility to understand internal business or IT process, best practices and translate into technology needs/opportunities
  • Strong collaboration, stakeholder management and communication skills – including verbal, written, and negotiation
  • Strong Listener. Be able to patiently listen to understand the business needs
  • Strong work ethic, a sense of business urgency, and the ability to work effectively with many deadlines in a complex matrix organization
  • Proven track record of critical thinking, analytical ability, operational excellence, and detail orientation
  • Possesses ability to analyze make critical decisions based on analysis
  • Ability to find innovative ways to resolve problems
  • Experience in stakeholder management, dealing with middle management up to executive level
  • Specific experience in the Life Sciences/Pharma/Medical Devices/Healthcare industries is preferred
  • Demonstrated expertise in technology environments relevant to Biotech Clinical Manufacturing production
  • Experience with platforms critical to Biologics Clinical Manufacturing (e.g., MES / Electronic Batch Records, ERP Mfg, CMMS, Digital Process and Automation, Historian, IOT, etc. ) and a willingness to learn and adapt to new Biologics Clinical Manufacturing IT systems as they emerge
  • Extensive knowledge of Agile methodologies and tools (e.g. Jira, Asana, etc.), with proven abilities to apply these in supporting IT solutions that meet both business needs and clinical manufacturing objectives.
  • Experience in programming environments (e.g., Python, R) and cloud computing platforms (e.g., AWS), especially those relevant to data and analytics in life sciences is very desirable
  • Awareness of emerging IT trends and technologies (e.g. GenAI, Digital Twin, Process Analytical Technology, AI/ML Predictive Analytics, etc.), with a commitment to continuous learning, especially in areas relevant to biopharmaceutical research
Responsibilities
  • Cultivates and demonstrates a working knowledge of Biologics Clinical Manufacturing, Facilities & Engineering and Quality Control.
  • Participates in short- and long-term strategic planning session to improve business or IT processes through capability development
  • Participates in discovery sessions to identify opportunities for improvements in business capabilities or IT operations and formulate proposals for cost-effective solutions based on engagement, project, and operations activities
  • Demonstrates how capability enablement can assist selected departments / business areas and how platforms and solutions can support the achievement of short- and long-term business or IT capability goals
  • Establishes and maintains a strategic relationship with select functional level stakeholders based on experience and contribution to business operations
  • Participates in the development of business use cases, cost structure, and ROI model in support of investment projects and activities to build IT Roadmap and demonstrate clarity on how solution provides business value
  • Actively communicates with select business capabilities, IT, vendors and other stakeholders, to ensure awareness of vision, roadmap, progress, risks, and results associated with a key capability
  • Works with appropriate business Subject Matter Experts (SMEs) and business stakeholders to proactively identify and evaluate risks associated with business decisions that may impact a capability enablement
  • Participates in workshop sessions for incremental roadmap assessments and business alignment
  • Educates and aligns business digital vision and needs with IT initiatives, beyond technical feasibility
  • Illustrates contextual insight to ensures IT development supports revenue growth, compliance, and customer outcomes
  • Presents Voice of the Business by capturing evolving business needs and translates them into system capability targets
  • Participates in workshop sessions for Strategic Planning to connect business objectives to long-term IT capabilities
  • Provides input to anticipates changes in scale, market, or regulation to future proof and incorporate them into the roadmap
  • Participates in cross-functional teams to align product, operations, and IT on a single direction
  • Provides input to Business Translation Layer to ensure delivery solves business problems to enable DevOps team for code delivery
  • Reduces rework by validating business requirements upfront, avoiding costly misalignment during implementation
  • Enhances change management with increased adoption by ensuring workflows and training match the business context
  • Works with business process owners and DevOps leads to cultivate appropriate solution required to meet business or IT objectives
  • Engages Domain Architecture team to align long-term technology strategy with business objectives
  • Sets proper expectations with business and supports escalation and resolution through negotiation or governance mechanisms
  • Participates in analysis of current and future technology trends to determine impact to the business, provides input to IT team lead to promote capability enablement and benefit realization
  • Communicates to other IT domains for awareness of key capability aspects, how they operate and how they are impacted
  • Participates in tracking business KPIs post-implementation
  • Provides feedback loops for product enhancements and roadmap updates
  • Provides input to ensure IT delivery remains aligned with evolving business needs
  • Provides input to IT team lead to help prioritize the flow of work in program backlog
  • Fosters a team environment and shares relevant information with IT team members
  • Create Inclusion - knowing the business value of diverse teams, modeling inclusion, and embedding the value of diversity in the way they manage their teams.
  • Develop Talent - understand the skills, experience, aspirations and potential of their employees and coach them on current performance and future potential.
  • Empower Teams - connect the team to the organization by aligning goals, purpose, and organizational objectives, and holding them to account.
Desired Qualifications
  • Specific experience in the Life Sciences/Pharma/Medical Devices/Healthcare industries is preferred.
  • Demonstrated expertise in technology environments relevant to Biotech Clinical Manufacturing production
  • Experience with platforms critical to Biologics Clinical Manufacturing (e.g., MES / Electronic Batch Records, ERP Mfg, CMMS, Digital Process and Automation, Historian, IOT, etc. ) and a willingness to learn and adapt to new Biologics Clinical Manufacturing IT systems as they emerge
  • Experience in programming environments (e.g., Python, R) and cloud computing platforms (e.g., AWS), especially those relevant to data and analytics in life sciences is very desirable
  • Awareness of emerging IT trends and technologies (e.g. GenAI, Digital Twin, Process Analytical Technology, AI/ML Predictive Analytics, etc.), with a commitment to continuous learning, especially in areas relevant to biopharmaceutical research

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Twice-yearly lenacapavir can expand HIV prevention adoption through better adherence.
  • South Africa’s rollout validates a scalable access model in high-burden markets.
  • Islatravir/lenacapavir topline results create a weekly HIV treatment extension opportunity.

What critics are saying

  • Generic licensing limits lenacapavir pricing power in low-income markets.
  • Biktarvy concentration exposes revenue to pricing pressure and regimen switching.
  • Acquisition charges and debt issuance keep near-term earnings under pressure.

What makes Gilead Sciences unique

  • Gilead leads with HIV prevention and treatment, anchored by lenacapavir and Biktarvy.
  • It operates across virology, oncology, liver disease, and inflammatory therapeutics.
  • Its licensing network spans 120 low- and lower-middle-income countries for lenacapavir.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Gilead Sciences who can refer or advise you

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Good News Network
Jun 9th, 2026
Staggering results show hiv-transmission reduced 100% with twice-yearly Lenacapavir injection.

Staggering results show hiv-transmission reduced 100% with twice-yearly Lenacapavir injection. Jun 9, 2026 A 2-stage trial testing a new and acclaimed HIV-prevention drug has shown almost unthinkable results of no new infections among a sample size of 3,200 participants. Called PURPOSE 1, the aim of the first trial was testing a subcutaneous injection of the drug Lenacapavir given twice a year to people in a high-HIV-incidence country, which in this case was Uganda or South Africa. The results were nothing short of extraordinary - 100% efficacy, not a single young woman contracted HIV. This was followed up by PURPOSE 2, which expanded the geographical area significantly to more countries on more continents, and expanded the pool of individuals from beyond just young women to men - and to those of all ages. 5,000 participants took part. The result was the same: 99.9% reduction in infection rates. Both were considered phase 3 clinical trials, and were conducted in a randomized, double-blinded protocol, but were not tested against a placebo. Instead, the Lenacapavir injections were compared to the current standard of HIV prevention - a pill called Truvada or Descovy taken daily. These both were also found to prevent HIV transmission by 99.9% during development, but must be taken every day to achieve this level of protection. As anyone who's tried to stick to a once-a-day pill regime long-term will agree, it's not an easy thing to maintain month after month. By contrast, the twice-yearly injections are much easier to adhere to, and they also come with the added benefit of removing the social stigma of being seen taking a daily pill and therefore at risk of HIV transmission. This can be particularly alleviating in high-HIV-prevalent countries where male homosexuality is illegal, such as Uganda. Indeed the superiority of a twice-yearly injection was so clear that both PURPOSE trials were halted early over ethical reasons. A 52-week follow-up screened for HIV developments. Lenacapavir was named by Science Magazine as the Breakthrough of the Year in 2024, and was approved by the FDA for use in humans under the brand name Yeztugo. It works to break down the HIVs capsid shell by binding to an "highly conserved" protein on the exterior. That means that no matter how many times or into what form the virus mutates, the exterior shell protein remains - presenting the perfect target for the drug. In layman's terms, the drug then works through the protein to disrupt the capsid shell, which the virus 'takes down' and 'builds up' several times during its lifecycle with perfect geometric precision. The disruption prevents the virus from completing its life cycle. Initial R&D, regulation compliance, and proof of efficacy and safety requirements mean that producing Lenacapavir has cost its developer, Gilead Sciences, an undisclosed total cost that would be reasonable to estimate at well over a billion dollars based on normal pharma development costs. Gilead has nevertheless committed to providing the drug at cost in certain low-income regions and has licensed generic manufacturers to produce it for approximately $40 per year in 120 low and middle-income countries starting in 2027.

AllSci
Apr 10th, 2026
Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access.

Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access. April 10, 2026 Tempus AI, Inc. (Nasdaq: TEM), a Chicago-based technology company, announced an expanded multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at advancing Gilead's oncology pipeline through enterprise-wide access to Tempus's AI-driven Lens platform and multimodal real-world evidence datasets. The agreement covers multiple oncology indications; no specific drug candidates or therapeutic targets were disclosed as part of the transaction. Financial terms were not disclosed. Under the expanded arrangement, Gilead gains enterprise-wide access to the Tempus Lens platform, which integrates de-identified genomic, clinical, imaging, and outcomes data into a unified repository supported by AI-driven analytical tooling. Disclosed applications include trial design, indication selection, biomarker strategy, health outcomes analysis, and clinical real-world evidence generation. Tempus will also provide dedicated analytical services under the agreement. The collaboration represents an expansion of a pre-existing relationship in which Gilead had previously used Tempus data to inform oncology R&D initiatives, and follows on from a collaboration between Tempus and Daiichi Sankyo announced in March 2026. The collaboration is designed to operate across Gilead's oncology pipeline rather than in support of a single program. Gilead's oncology portfolio includes sacituzumab govitecan, axicabtagene ciloleucel, brexucabtagene autoleucel, and magrolimab, among other assets, though none were named as specific beneficiaries of the arrangement. The platform's stated functions - indication prioritization, patient stratification, biomarker pre-validation, and real-world evidence generation - are applicable across tumor types and development stages. Your email address will not be published. Required fields are marked *

Yahoo Finance
Apr 9th, 2026
Gilead exercises option on Kymera's oral CDK2 degrader KT-200, triggering $45M milestone

Kymera Therapeutics will receive a $45 million milestone payment following Gilead Sciences' decision to exercise its option to exclusively licence KT-200, a first-in-class oral CDK2 molecular glue degrader development candidate. Gilead will advance the programme into IND-enabling studies, targeting an IND filing in 2027. KT-200 is expected to become the first molecular glue discovered by Kymera to enter clinical trials. The drug candidate demonstrated low-nanomolar degradation of CDK2 in preclinical testing, with robust activity in cancer cell lines and favourable safety profiles. It targets cancers driven by CCNE1 amplification, including advanced breast cancer. Under their collaboration agreement, Kymera is eligible for up to $750 million in total payments and has received $85 million to date. The company will also receive tiered royalties on net product sales.

Genetic Engineering and Biotechnology News
Apr 7th, 2026
Gilead to acquire Tubulis for up to $5B, expanding cancer ADC capabilities.

Gilead to acquire Tubulis for up to $5B, expanding cancer ADC capabilities. April 7, 2026 Gilead Sciences has agreed to acquire German-based Tubulis for up to $5 billion, the companies said today, in a deal designed to expand the buyer's antibody-drug conjugate (ADC) capabilities with a focus on fighting cancer. Headquartered in Munich, privately held Tubulis has developed next-generation ADC candidates based on its own conjugation, linker and payload technologies intended to more selectively deliver diverse payloads to tumors deemed to be of high unmet need. The companies said Tubulis' programs and platforms have broad potential across multiple tumor types, complementing Gilead's development and commercialization expertise in oncology. "We like the strategic fit and deal terms of the Tubulis (private) acquisition," Daina M. Graybosch, PhD, senior managing director, immuno-oncology and a senior research analyst at Leerink Partners, wrote this morning in a research note. "This is more than an oncology bolt-on; we see real platform value in application of Tubulis' ADC technologies to other therapeutic areas, namely virology." Tubulis' lead pipeline candidate, TUB-040, is a sodium-dependent phosphate transport protein 2B (NaPi2b)-targeting topoisomerase-I inhibitor (TOPO1i) ADC that is now under study in the Phase Ib/II NAPISTAR1-01 trial (NCT06303505) assessing its safety, pharmacokinetics, and preliminary efficacy as a treatment for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). In October at the European Society for Medical Oncology (ESMO), Graybosch noted, Tubulis presented data for TUB-040 showing a confirmed 50% overall response rate (ORR) and a 60% unconfirmed ORR across dose levels and irrespective of target antigen - results that were competitive with more mature datasets from leading TOPO1i ADCs. "Though the dataset was early, and our primary outgoing question was how durability would mature, we suspect that Gilead saw durability maturing positively in their diligence," Graybosch added. "If TUB-040 proves active in NSCLC, the program could complement their Trodelvy and IO [immune-oncology] lung programs. We wonder if Gilead saw early clinical NSCLC data in their diligence and if excitement around the emerging signal drove some of Tubulis' valuation." Another Tubulis pipeline candidate, TUB-030, is a 5T4-targeting ADC that according to the companies has shown promising initial clinical data across various solid tumor types. TUB-030 is currently under study in the Phase I/IIa 5-STAR 1-01 trial (NCT06657222), a first-in-human study which aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-030 as a monotherapy in patients with advanced solid tumors. Tubulis has said it is developing TUB-030 for up to 13 undisclosed solid tumor indications. Partners since 2024. The acquisition deal follows a two-year, up-to-$465 million collaboration with Tubulis launched in December 2024. Gilead gained access to Tubulis' Tubutecan and Alco5 platforms after signing an exclusive option and license agreement to discover and develop an ADC against a solid tumor target. At the time, Gilead agreed to pay Tubulis $20 million upfront, received an option that if exercised would have given Tubulis an additional $30 million - plus up to $415 million in payments tied to achieving development and commercialization milestones, as well as mid-single to low double-digit tiered royalties on sales of marketed products resulting from the collaboration. "Today's agreement follows a two-year collaboration with Tubulis, which has given us strong conviction in their programs and research capabilities," Gilead Chairman and CEO Daniel O'Day said in a statement. "The agreement to acquire Tubulis is a significant milestone in Gilead's progress in oncology. The company brings a clinical-stage candidate that is a potential new treatment for ovarian cancer, as well as a next-generation ADC platform and a promising early pipeline." "Bringing this potential into Gilead would further expand what is already the strongest and most diverse pipeline in our company's history," O'Day declared. Investors appeared less enthusiastic about the acquisition, as shares of Gilead dipped 1.7% in early Tuesday trading to $137.80 as of 12:01 p.m. ET. Tubulis is Gilead's third announced acquisition this year. The biotech giant announced plans in March to buy Ouro Medicines for up to $2.18 billion, and in February agreed to acquire Arcellx for up to $7.8 billion - for which it agreed last week to extend its tender offer until 5 p.m. ET on April 24. Under the acquisition deal, Gilead agreed to acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash payable at closing, and up to $1.85 billion in payments tied to milestones. The transaction is expected to close in the second quarter subject to expiration or termination of specified regulatory filings and other customary conditions. Upon closing of the deal, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation, building on its integrated discovery, manufacturing, and clinical capabilities to advance next generation ADCs. Gilead said it plans to finance the transaction with a combination of cash on hand and senior unsecured notes. Gilead finished 2025 with $10.605 billion of cash, cash equivalents and marketable debt securities, up from $9.991 billion as of December 31, 2024.

Dealroom.co
Apr 7th, 2026
Gilead Sciences company information, funding & investors

Gilead Sciences, biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases. Here you'll find information about their funding, investors and team.